1292280-39-7

Upstream product

• 126910-37-0 1-phenyl-2,3,4,5-tetramethyl-1,3-cyclopentadiene 
• 93768-83-3 (2,3,4,5-tetramethylcyclopenta-2,4-dien-1-yl)-benzene 
• 64417-14-7 3-phenyl-1,2,4,5-tetramethyl-1,3-cyclopentadiene 
• 12112-67-3 bis(1,5-cyclooctadiene)diiridium(I) dichloride 

Downstream Products

• 1326301-06-7 [(phenyltetramethylcyclopentadienyl)Ir(phpy)Cl] 
• 1292280-46-6 [(η5-C5Me4C6H5)lrCI(bipy)]PF6 
• 1292280-42-2 [Ir(η⁵‐Cp^ph)(phen)Cl]PF₆ 
• 1351363-97-7 [(η5-C5Me4C6H5)lr(dpq)Cl]PF6 

Relevant academic research and scientific papers

Regiodivergent Iridium(III)-Catalyzed Diamination of Alkenyl Amides with Secondary Amines: Complementary Access to γ- Or δ-Lactams

Alkenyl N-pivaloylhydroxamates undergo an Ir(III)-catalyzed diamination of the alkene with simple exogenous secondary amines under extraordinarily mild reaction conditions. The regioselectivity of the diamination is controlled by the solvent and the electronics of the cyclopentadienyl (Cpx) ligand on Ir. On the basis of a set of mechanistic experiments, we propose that the relative rates of Ir(V)-nitrenoid formation versus attack on the amido-Ir-coordinated alkene by the exogenous amine determine the outcome of the reaction.

Extending the range of pentasubstituted cyclopentadienyl compounds: The synthesis of a series of tetramethyl(alkyl or aryl)cyclopentadienes (Cp?R), their iridium complexes and their catalytic activity for asymmetric transfer hydrogen

Tetramethyl(alky or aryl)cyclopentadienes were synthesized and the organometallic half-sandwich iridium complexes of the form [(η5-Cp?R)Ir(aa)Cl], Cp?R = tetramethyl(phenyl)cyclopentadienyl (Cp?

Metal iridium-ferrocene Schiff base complex and preparation method thereof

The invention discloses a metal iridium-ferrocene Schiff base complex as well as a preparation method and anti-cancer application thereof. The structural formula is as shown in formula (I), R1 is hydrogen, methyl or phenyl, R2 is methyl or phenyl, and R3 is hydrogen or methyl. The growth inhibition rate of the target complex on human alveolar basal epithelial cancer cells (A549) and cervical cancer cells (Hela) is tested. Compared with a ferrocene thiosemicarbazide Schiff base ligand, a basic metal iridium dimer and a cis-platinum drug, the target complex shows potential anti-cancer activity, and the synergistic effect of the ferrocene and the metal iridium complex on the anti-cancer activity is proved. The target complex can be accumulated in lysosome tissues of A549 cells and cause lysosome damage, thereby causing cancer cell death.

Preparation and the anticancer mechanism of configuration-controlled Fe(ii)-Ir(iii) heteronuclear metal complexes

A series of configuration-controlled Fe(ii)-Ir(iii) heteronuclear metal complexes, including ferrocene and half-sandwich like iridium(iii) complex units, have been designed and prepared. These complexes show better anticancer activity than cisplatin under the same conditions, especiallycis-configurational ones. Laser confocal microscopy analysis confirms that the complexes follow a non-energy-dependent cellular uptake mechanism, accumulate in lysosomes (pearson co-localization coefficient: ～0.7), lead to lysosomal damage, and eventually induce apoptosis. These complexes can reduce the mitochondrial membrane potential, disturb the cell circle, catalyze the oxidation of nicotinamide-adenine dinucleotide (NADH) and increase the levels of intracellular reactive oxygen species (ROS), following an anticancer mechanism of oxidation. In addition, the complexes could bind to serum protein, and transport through it. Above all, the Fe(ii)-Ir(iii) heteronuclear metal complexes hold promise as potential anticancer agents for further study.

Fluorescent iridium(iii) coumarin-salicylaldehyde Schiff base compounds as lysosome-targeted antitumor agents

Six fluorescent half-sandwich iridium(iii) coumarin-salicylaldehyde Schiff base (O^N) compounds ([(?5-Cp*)Ir(O^N)Cl]) were prepared and characterized. The introduction of a coumarin unit increased the antitumor activity (IC50: 9.9 ± 0.1 μM-40.7 ± 12.9 μM) of these compounds, the best of which was nearly two times that of clinical cisplatin. The results of laser confocal microscopy demonstrated that these compounds possessed an energy-dependent cellular uptake mechanism, accumulated in the lysosomes (Pearson co-localization coefficient: ~0.7), damaged the integrity of the lysosomes, and induced apoptosis. The compounds could also decrease the mitochondrial membrane potential, catalyze the oxidation of the coenzyme (nicotinamide-adenine dinucleotide) and improve the levels of the intracellular reactive oxygen species, following an antitumor mechanism of oxidation. Additionally, these compounds could block the metastasis of tumor cells. Above all, these iridium(iii) compounds show potential as antitumor agents with dual functions: lysosomal damage and anti-metastasis.

Iron-iridium heteronuclear metal complex, and preparation method and application thereof

The invention discloses an iron-iridium heteronuclear metal complex, and a preparation method and an application thereof. The structural formula of the compound is represented by formula (I), and R inthe formula (I) is hydrogen, an alkyl group or an aryl group. Results of experiments for testing the inhibition rate of the target complex on the growth of human alveolar basal epithelial cancer cells (A549) and cervical cancer cells (Hela) show that compared with a ferrocene bipyridine derivative, a metal iridium dimer, a basic metal iridium bipyridine complex and cis-platinum, the target complex especially the complex with a cis-configuration has good anticancer activity, and the synergistic anticancer effect of ferrocene and the metal iridium complex is proved. When the substituent R is from a methyl group to a phenyl group, the activity of the complex is improved, which proves the synergistic effect of improving the electron donating capacity of the ligand on improving the anticanceractivity of the target complex. The target complexes may accumulate within the lysosome of the cell and result in lysosome damage, resulting in cancer cell apoptosis.

With anticancer activity of ion iridium complex and its preparation method, application (by machine translation)

The invention relates to a metal complex, in particular relates to a ion iridium complexes with anticancer activity and its preparation method, application, which belongs to the chemical-pharmaceutical field. The complex structural formula is: , The present invention provides organic iridium complex is a phosphorus-oxygen atom with the iridium coordination complex, has high anticancer activity, small side effect, property is good, and is not easy to produce the drug resistance; the invention provides a preparation method, the synthesis efficiency is high, in the preparation of the complexes in biomedical Sciences has broad application prospects; the invention [P, O] introduced into the neutral ligands of this complex has androgenic activity, for the follow-up anti-cancer pharmaceutical ligand synthetic study provides a new line of research. (by machine translation)

Rapid Access to Derivatized, Dimeric, Ring-Substituted Dichloro(cyclopentadienyl)rhodium(III) and Iridium(III) Complexes

The present work describes the design and synthesis of a series of rhodium and iridium dimers [(η5-ring)MCl]2(μ2-Cl)2 (where (η5-ring)MCl = (η5-Me4C5R)Rh(III)Cl or (η

NOVEL IRIDIUM/RHODIUM ANTI-CANCER COMPOUNDS

The present invention relates to novel iridium and/or rhodium containing complexes for use as a cytotoxic, such as an anti-cancer agent. There is also provided a method of preparing said compounds.